Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Shareholder Meeting (November 2024)
16 slides from Pyc Therapeutics's shareholder meeting presentation, Nov 13, 2024
Slide 1: 2024 AGM Chairman's Address and CEO Presentation
13 November 2024 2024 AGM Chairman’s Address and CEO Presentation PYC Therapeutics (ASX:PYC) (PYC or the Company) submits the following Chairman’s Address and CEO Presentation to be made at the 2024 Annual General Meeting being held today at The Harry Perkins Institute of Medical Research, at 9am AW
Slide 2: For personal use only
This ASX announcement was approved and authorised for release by the CEO of PYC Therapeutics Limited CONTACTS: INVESTORS and MEDIA info@pyctx.com For personal use only pyctx.com | ACN 098 391 961 2
Slide 3: Chairman's Address
CHAIRMAN’S ADDRESS PYC is an emerging leader in the field of precision RNA therapies for patients with genetic diseases caused by haploinsufficiency in the eye, kidney and central nervous system. The Company is developing four first-in-class drug candidates in areas of severe unmet need for the tens
Slide 4: Chairman's Address (conclusion)
It is an exciting time for both patients and shareholders. Although much has been achieved, we look forward to more success from the hard work and commitment of the PYC team and I again recognise their achievements and thank them. And lastly, to shareholders both long standing and new – we appreciat
Slide 5: Life-changing science
For personal use only Life-changing science PYC AGM presentation November 2024
Slide 6: Disclaimer
Disclaimer The purpose of this presentation is to provide an update of the business which are outside PYC’s control. Important factors that could cause For personal use only of PYC Therapeutics Limited (ASX:PYC) [‘PYC’]. These slides have been actual results to differ materially from assumptions or
Slide 7: PYC's 2024 Highlights
PYC’s 2024 Highlights Patient impact • Patients with a progressive and irreversible blinding eye disease have improved vision following For personal use only treatment with PYC’s investigational drug candidate in combined Phase 1/2 studies • This is the first drug candidate for this indication to ha
Slide 8: PYC's 4-year operational roadmap
PYC’s 4-year operational roadmap Program 2025 2026 2027 2028 For personal use only RP11 Ph1/2 study Registrational study VP-001 NDA Product launch and Monogenic blinding eye 1 disease of childhood transition to commercial- Gene: PRPF31 Clinical proof-of-concept stage company Registrational efficacy
Slide 9: What is coming in 2025 for PYC?
What is coming in 2025 for PYC? • Progressing high propensity assets with market-leading potential into late-stage For personal use only (registrational) trials • Reading out on multiple human safety and efficacy milestones in areas of major unmet need • Moving a drug candidate with disease-modifyin
Slide 10: For personal use only
For personal use only “There’s a lot of demand right now for these types of companies…Companies that have programs with high probability of success in the clinic and the opportunity to quickly accelerate through clinical development.” PYC THERAPEUTICS 6 Endpoints News 31 October 2024 - Q&A: Jade CEO
Slide 11: RP11 program deep dive
RP11 program deep dive Program 2025 2026 2027 2028 For personal use only RP11 Ph1/2 study Registrational study VP-001 NDA Product launch and Monogenic blinding eye 1 disease of childhood transition to commercial- Gene: PRPF31 Clinical proof-of-concept stage company Registrational efficacy ADOA Ph1/2
Slide 12: ADOA deep dive
ADOA deep dive Program 2025 2026 2027 2028 For personal use only RP11 Ph1/2 study Registrational study VP-001 NDA Product launch and Monogenic blinding eye 1 disease of childhood transition to commercial- Gene: PRPF31 Clinical proof-of-concept stage company Registrational efficacy ADOA Ph1/2 study R
Slide 13: Polycystic kidney disease deep dive
Polycystic kidney disease deep dive Program 2025 2026 2027 2028 For personal use only RP11 Ph1/2 study Registrational study VP-001 NDA Product launch and Monogenic blinding eye 1 disease of childhood transition to commercial- Gene: PRPF31 Clinical proof-of-concept stage company Registrational effica
Slide 14: Phelan-McDermid Syndrome deep dive
Phelan-McDermid Syndrome deep dive Program 2025 2026 2027 2028 For personal use only RP11 Ph1/2 study Registrational study VP-001 NDA Product launch and Monogenic blinding eye 1 disease of childhood transition to commercial- Gene: PRPF31 Clinical proof-of-concept stage company Registrational efficac
Slide 15: Where will we be at this time next year?
Where will we be at this time next year? Program 2025 2026 2027 2028 For personal use only RP11 Ph1/2 study Registrational study VP-001 NDA Product launch and Monogenic blinding eye 1 disease of childhood transition to commercial- Gene: PRPF31 Clinical proof-of-concept stage company Registrational e
Slide 16: Q&A
For personal use only Q&A PYC THERAPEUTICS 12
PYC Therapeutics — Shareholder Meeting (November 2024) on 6ix